Correction to: SEOM clinical guidelines for anaemia treatment in cancer patients (2020)

542 Background: Many ER-positive, HER2-negative breast cancer patients are treated by adjuvant chemotherapy according to current clinical guidelines. We retrospectively assessed whether the combined gene expression/ clinicopathological EndoPredict-clin (EPclin) score improved the accuracy of risk classification in addition to considering clinical guidelines. Methods: Three clinical breast cancer guidelines (National Comprehensive Cancer Center Network (NCCN), German S3 and St. Gallen 2011), and the EPclin score - assessed by quantitative RT-PCR in formalin-fixed paraffin-embedded tissue - were used to assign risk groups in 1,702 ER-positive, HER2-negative breast cancer patients from two randomized phase III trials (Austrian Breast and Colorectal Cancer Study Group 6 and 8) treated with endocrine therapy only. Results: Although all analyzed clinical guidelines identified a low-risk group with improved metastasis-free survival, the overwhelming majority of all patients (81-94%) were classified as intermediate / high risk. In contrast to that, the EPclin classified only 37% of all patients as high risk and that stratification resulted in the best separation between low and high risk groups (p < 0.001, HR = 5.11 (3.48-7.51). Consequently, the majority of all patients deemed intermediate / high risk by the clinical guidelines was re-classified as low risk by the EPclin score. Kaplan Meier analyses demonstrated that the re-classified subgroups (47 to 57% of all patients) had an excellent 10-year metastasis-free survival of 95% comparable to the clinical assigned low-risk groups although encompassing a higher proportion of the trial patients. Conclusions: The EPclin score predicted distant recurrence more accurately than all three clinical guidelines and is especially useful to reclassify patients considered as intermediate / high risk by the guidelines. The data suggests that the EPclin score provides clinically useful prognostic information beyond common clinical guidelines and can be used to accurately identify the clinically relevant group of patients who are adequately and sufficiently treated with adjuvant endocrine therapy alone.

Download Full-text

SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy

Clinical & Translational Oncology ◽

10.1007/s12094-010-0594-5 ◽

2010 ◽

Vol 12 (11) ◽

pp. 770-774 ◽

Cited By ~ 7

Author(s):

Jesús García Gómez ◽

M. Eva Pérez López ◽

Jesús García Mata ◽

Dolores Isla Casado

Keyword(s):

Cancer Patients ◽

Clinical Guidelines ◽

Antiemetic Prophylaxis

Download Full-text

Multidisciplinary consensus on the criteria for fertility preservation in cancer patients

Clinical & Translational Oncology ◽

10.1007/s12094-021-02699-2 ◽

2021 ◽

Author(s):

A. Santaballa ◽

C. Márquez-Vega ◽

Á. Rodríguez-Lescure ◽

Á. Rovirosa ◽

L. Vázquez ◽

...

Keyword(s):

Cancer Patients ◽

Fertility Preservation ◽

Radiation Oncology ◽

Clinical Guidelines ◽

Medical Oncology ◽

Reproductive Age ◽

Spanish Society ◽

Paediatric Haematology ◽

Adequate Information ◽

Oncological Patients

AbstractInfertility is one of the main sequelae of cancer and its treatment in both children and adults of reproductive age. It is, therefore, essential that oncologists and haematologists provide adequate information about the risk of infertility and the possibilities for its preservation before starting treatment. Although many international clinical guidelines address this issue, this document is the first Spanish multidisciplinary guideline in paediatric and adult oncological patients. Experts from the Spanish Society of Medical Oncology, the Spanish Fertility Society, the Spanish Society of Haematology and Haemotherapy, the Spanish Society of Paediatric Haematology and Oncology and the Spanish Society of Radiation Oncology have collaborated to develop a multidisciplinary consensus.

Download Full-text

Smoking cessation after lung cancer diagnosis improves disease prognosis

Malignant tumours ◽

10.18027/2224-5057-2021-11-3-15-22 ◽

2022 ◽

Vol 11 (3) ◽

pp. 15-22

Author(s):

D. G. Zaridze ◽

A. F. Mukeria ◽

O. V. Shangina ◽

I. S. Stilidi

Keyword(s):

Lung Cancer ◽

Smoking Cessation ◽

Cancer Patients ◽

Cancer Mortality ◽

Clinical Guidelines ◽

Cost Effective ◽

Clinical Value ◽

Lung Cancer Diagnosis ◽

Specific Cancer ◽

American Society

Abstract: The presented clinical and epidemiological study is the world»s first large prospective study of the effect of smoking cessation after lung cancer (LC) diagnosis on the prognosis. Follow‑up of 517 patients with NSCLC for 7 years in average showed that continued smoking after diagnosis is a serious negative prognostic factor. At the same time smoking cessation improves OS and PFS by 22,6 months and specific cancer mortality by 22,8 months; reduces the risk of all‑cause mortality by 33 %, the risk of progression by 30 % and the risk of specific cancer mortality by 25 %. Almost 60 % of patients in our study continued smoking after diagnosis. Consequently, they had avoidable excess mortality which eventually reduced their life by 2 years.The positive effect of smoking cessation after diagnosis found in our study significantly exceeds the «meaningful benefit» (improvement in median overall survival by 2,5–6 months) for antineoplastic agents proposed by the American Society of Clinical Oncology (ASCO). Moreover, the study suggests that the benefits of smoking cessation after LC diagnosis are at least equal or superior to the significant results obtained in clinical studies of the effectiveness of innovative treatments.We hope that the results of our study will contribute to the inclusion of smoking cessation in clinical guidelines for the treatment of NSCLC and other cancers. The treatment program for cancer patients should include evidence‑based methods of smoking cessation presented in the form of «Clinical Guidelines for Smoking Cessation for Cancer Patients».Treating smoking in cancer patients is cost‑effective for the health care system, especially when compared to other treat‑ments. Conversely, continuing smoking after diagnosis significantly increases treatment costs.The introduction of recommendations on smoking cessation and treatment of nicotine addiction into the practice will improve the overall mortality rate by 30–35 % in more than 60,000 patients annually diagnosed with lung cancer in Russia. The clinical value of this method is obvious, since it has been proven to be highly efficient in improving the life expectancy of patients, and, ultimately, in reducing cancer mortality in Russia.

Download Full-text